Australia's largest stock trading and investment forum Australia's #1 stock forum

IHL

0.00%

4.1¢ incannex healthcare limited

Don’t Freak Out. It Isn’t the End of the Line for Psychedelic...

First 55 Last

Share
Profile

Follow
Breakingsystem

386 Posts.

137

07/06/24

13:24

Post #: 74215417
Share

Originally posted by Flectional: ↑

your take is interesting in a number of areas - and not accurate dc

the fact that the recipient can identify they have taken a sugar pill ( in this particular case) rather than the drug under trial does not indicate an adverse outcome for the trail endpoints - rather the reverse is true and substantially so - to undergo the psychotherapy set after taking the trial medication and finding no differentiation or change in the patient condition would indicate immediately to the patient they have been dosed with an ineffective medication ....in this case a sugar pill.
This is exactly what you would want if you were conducting the trial - why? this is the opposite of the placebo effect verifying the test cohort outcomes comparative to the outcomes of those on the real medication.

the FDA committee indicated major failures with the trial design that Lykos conducted - blinding protocols being a major factor - as a result blinding must be administered, scrutinized and meticulously aligned with the psychotherapy set for quality data to be in evidence - this was not the case with this Lykos trial - as the FDA stated they in fact ignored procedural recommendations by the advisory contributing to the trial failure.

Clarion outcomes to date (Dr Paul and PSI -GAD) have had no such issues
PsiGAD-1 is a randomised triple-blind active-placebo-controlled Phase 2 trial. The primary objective of the study is to determine whether a 7-week program of psilocybin-assisted psychotherapy for GAD is superior to active placebo-assisted psychotherapy in decreasing symptoms of GAD, as measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) from baseline to week 11. Safety and tolerability were assessed, as well as other secondary objectives of efficacy and quality of life.

Expand

Don’t Freak Out. It Isn’t the End of the Line for Psychedelic Medicines

https://www.barrons.com/articles/mmda-ecstacy-psychedelic-medicines-fda-7130bf1c

IHL Price at posting: 4.1¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

SPR

Dalgaranga gold play's increase in MRE a 'pivotal moment' for Spartan

ASX Market Open: Australian market rallies on US rebound, as tech stocks perform well, and Biden steps down

EMV

EMVision Medical successfully fabs first prototype of First Responder brain scan device – portable enough for a backpack

SRG

SRG Global flags FY24 earnings just short of $100M; sees 10% jump in FY25

ITM

iTech Minerals flags high-grade rockchip finds, boasting one sample at +18% copper. What lies underground remains to be seen